Equities

Alliance Pharma PLC

Alliance Pharma PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)55.93
  • Today's Change0.229 / 0.41%
  • Shares traded305.39k
  • 1 Year change-46.43%
  • Beta0.9594
Data delayed at least 20 minutes, as of Sep 30 2022 15:59 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Alliance Pharma plc is a United Kingdom-based holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's asset portfolio focused on two areas: Consumer Healthcare brands and Prescription Medicines. It holds marketing rights to approximately 80 consumer healthcare brands and Prescription Medicines, which are sold worldwide in approximately 100 countries. Its products include Aloclair, Alliance Calcium Syrup, Aiweidi, Biodermatin, Biotaches, Changmin, Decapional, Dermachronic, Dermacide, Dervida, Effadiane, Fazol, Flammacerium, Gen-Ongles, Irenat, Malunjunshe, MolluDab, Neostigmine and Nu-Seals and other. The Company’s brands also include Kelo-Cote, Nizoral, Amberen, MacuShield, Vamousse, Hydromol, Forceval, Ashton & Parsons, Anbesol, and Aloclair. Its geographical area includes Europe, Middle East and Africa (EMEA), Asia Pacific and China (APAC) and Americas (AMER).

  • Revenue in GBP (TTM)163.34m
  • Net income in GBP12.18m
  • Incorporated2001
  • Employees250.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
APH:LSE since
announced
Transaction
value
Mitchell-Vance Laboratories LLCDeal completed21 Mar 202221 Mar 2022Deal completed-49.88%19.40m
Data delayed at least 20 minutes, as of Sep 30 2022 15:59 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Northern Data AG14.46m-74.40m249.82m162.00--0.9852--17.28-7.25-7.251.4112.06------101,094.80--20.18--33.1637.2050.93-514.4885.770.301-0.52520.25190.001,059.28485.60440.81------
Avacta Group Plc2.94m-26.37m260.37m133.00--6.28--88.53-0.1057-0.10550.01180.16230.051414.040.814522,112.78-46.08---49.61---4.28---896.77--7.91-262.010.0397--37.17---60.85------
Selvita SA67.84m2.63m280.43m856.0083.215.1929.354.131.011.0126.0816.190.853831.545.26496,041.004.25--5.36--68.06--4.98--1.945.010.4173--122.46---17.22------
AB Science SA1.42m-12.77m286.11m98.00------201.64-0.3029-0.30290.0338-0.43630.06311.014.8316,397.96-56.76-69.55-265.60-203.8993.0991.10-899.94-1,273.481.03-321.12----1.521.283.87--1.48--
Arcticzymes Technologies ASA12.24m4.36m305.70m46.0071.9013.2164.8924.971.001.002.845.470.5221.087.393,165,718.0018.6013.0919.7315.4195.4982.3035.6320.6313.93--0.0568--36.9412.22-37.12--53.66--
DBV Technologies SA5.25m-90.13m315.38m226.00------60.11-1.86-1.860.1085-----------------------1,717.80-1,272.93---586.89-----49.38-10.6938.59------
Mithra Pharmaceuticals SA19.32m-82.32m315.68m248.00--9.40--16.34-2.11-2.110.49240.71420.05040.33230.889988,237.91-21.45-16.55-26.85-19.4233.4688.16-426.03-138.210.4207-7.010.859--151.030.1774-26.92--5.63--
Alliance Pharma plc163.34m12.18m319.04m250.0026.531.0713.911.950.02230.02230.30180.55010.30752.374.68640,560.802.294.232.504.8266.4263.247.4613.501.4713.440.314539.3325.7410.85-8.82-16.5631.706.92
Hyloris Pharmaceuticals SA2.91m-7.31m324.87m14.00--5.60--111.80-0.3162-0.31620.12592.350.0481--1.60238,478.30-12.09---13.52--96.17---251.63-----20.310.0011--1,669.14---62.06------
Deva Holding AS154.25m69.36m343.14m2.80k4.952.194.582.227.137.1315.8616.110.60741.335.761,250,830.0027.3120.9044.5230.8255.7053.4044.9731.541.07--0.46413.0025.0627.6279.6180.9442.36--
Bonesupport Holding AB20.75m-5.72m346.08m87.00--18.13--16.68-1.10-1.104.003.670.6990.55166.552,796,228.00-19.28-35.30-22.91-44.5789.4587.87-27.58-84.283.73-61.280.0763--17.7115.2715.66--19.98--
Gen Ilac ve Saglik Urunleri Sanayi ve190.06m28.90m348.36m542.0011.874.5511.111.832.012.0113.435.252.4112.2715.507,211,254.0036.54--52.32--19.43--15.19--1.95--0.1002--16.34--49.23------
Oxford BioMedica plc125.57m-24.54m356.95m959.00--1.44--2.84-0.262-0.2621.392.580.3784.452.52154,076.10-8.04-0.756-11.40-0.997660.4355.20-21.26-1.201.71-11.230.2925--62.7738.74404.42--7.94--
Philogen SpA2.20m-13.88m358.91m121.00--5.37--162.85-0.3957-0.39570.0632.590.02297.433.3320,628.10-14.41---16.24---207.97---630.01--9.25-96.740.1357---47.76---18.37------
Calliditas Therapeutics AB27.68m-49.56m377.43m137.00--6.48--13.64-11.80-11.806.6212.200.25938.229.725,198,909.00-46.78-31.46-53.50-34.6832.29---180.42-288.515.32--0.3885--26,141.08---15.41--145.12--
Data as of Sep 30 2022. Currency figures normalised to Alliance Pharma PLC's reporting currency: UK Pound GBX

Institutional shareholders

51.58%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 04 Apr 202253.91m9.99%
Slater Investments Ltd.as of 21 Mar 202249.69m9.21%
Kempen Capital Management NVas of 21 Mar 202239.39m7.30%
BlackRock Investment Management (UK) Ltd.as of 11 Aug 202226.35m4.88%
Investec Wealth & Investment Ltd.as of 21 Mar 202224.83m4.60%
Rathbone Investment Management Ltd.as of 21 Mar 202219.53m3.62%
Polar Capital LLPas of 21 Mar 202219.10m3.54%
RBC Global Asset Management (UK) Ltd.as of 08 Jun 202216.55m3.07%
Artemis Investment Management LLPas of 23 Mar 202116.30m3.02%
Janus Henderson Investors UK Ltd.as of 02 Jun 202212.75m2.36%
More ▼
Data from 30 Dec 2020 - 29 Jul 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.